Christopher P. Willits

Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.

M. Bergeron, G. Tonn, A. Olaharski, 2013, Toxicology and applied pharmacology.

Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS

C. Vandevert, T. Yednock, W. Zago, 2012, PloS one.

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.

Effects of single and multiple dose oral administration of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain and CSF of cynomolgus monkeys

R. Motter, D. Kholodenko, J. Sauer, 2010, Alzheimer's & Dementia.

Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration

R. Motter, D. Kholodenko, K. Hu, 2010, Alzheimer's & Dementia.

Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies

K. Quinn, R. Gullapalli, E. Goldbach, 2012, Drug delivery.

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.